Reyes D, Kurako K, Galvez-Jimenez N
Impulse control disorders (ICD) are increasingly recognized in patients with Parkinson’s disease (PD), particularly when treated with commonly used dopamine agonists such as pramipexole and ropinirole. Less evident is the possible association between monoamine oxidase inhibitors type B (MAO-B) and the development of ICD.
Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease modifying benefits with apparently good tolerability and safety profile in PD patients. Rasagiline is effective and well tolerated in PD as a monotherapy or in combination with levodopa.
Here, we report a patient with PD who developed ICD when treated de novo with MAO-B inhibitors.